Introduction
============

Ovarian cancer (OC) is the fifth most common cause of cancer-related deaths among women, with \~90% of these cases being epithelial ovarian cancer (EOC).[@b1-cmar-11-1907] At the start of 2018, there were an estimated 22,240 newly diagnosed cases and 14,070 deaths due to OC in USA.[@b1-cmar-11-1907] Although OC is less common than other cancers such as breast cancer, OC is attracting increased attention because of its poor prognosis. The 5-year survival rate for OC is only 47.2%. Although great progress has been made in cancer research, the overall prognosis for OC remains poor, because it is often diagnosed late in the disease process and has high recurrence rates after curative resection.[@b2-cmar-11-1907] Therefore, more effective and convenient markers must be identified to estimate the prognosis and select appropriate treatment strategies.

Over the past decades, many theories have been postulated to explain OC's etiology, and most of them converge on the role of inflammation.[@b3-cmar-11-1907] The systemic inflammatory response is associated with survival in advanced and localized cancers.[@b4-cmar-11-1907] Cancer-related inflammation includes modulating inflammatory cells and mediators such as cytokines and chemokines; however, these markers are not routinely measured despite their direct changes provide a direct surrogate marker of expression (eg, lymphocyte-to-monocyte ratio \[LMR\]).[@b4-cmar-11-1907] Several recent studies assessed the prognostic effect of pretreatment LMR among patients with OC, but the results were inconsistent. Elevated LMR was shown to increase survival in some,[@b5-cmar-11-1907]--[@b7-cmar-11-1907] but not all,[@b8-cmar-11-1907]--[@b11-cmar-11-1907] studies. As the statistical power of an individual study may be too weak to identify associations between pretreatment LMR and OC patient survival (sample size of most included studies was \<300 OC patients), a meta-analysis combining data from all published studies may be more convincing.

Thus, we conducted a meta-analysis to evaluate the prognostic effect of pretreatment LMR on OC patient survival, which included all eligible publications to date.

Materials and methods
=====================

This meta-analysis was conducted in accordance with the PRISMA ([Table S1](#SD1-cmar-11-1907){ref-type="supplementary-material"}).[@b12-cmar-11-1907]

Search strategies
-----------------

A comprehensive literature search of PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI, <http://www.cnki.net>), and the Wanfang databases (<http://www.wanfangdata.com.cn>) was conducted from inception through October 2018. The following search terms were used: (lymphocyte-to-monocyte or lymphocyte monocyte or lymphocyte-monocyte or lymphocyte to monocyte or lymphocyte/monocyte or LMR) AND (cancer\* or carcinoma\* or neoplasm\* or malignan\* or tumour\* or tumor\*) AND (ovary or ovarian) without language restriction (Supplementary materials). Related articles generated by Google Scholar (<http://scholar.google.com>) and PubMed were retrieved. We also scanned the reference lists of related articles to identify all potential useful studies on OC that might have been missed in our database searches.

Study selection
---------------

Inclusion criteria were as follows: 1) studies on patients with OC diagnosed histopathologically; 2) studies that assessed the prognostic value of pretreatment LMR among OC patients; 3) studies that reported the LMR cutoff value; 4) studies that reported sufficient information for calculating the HR and its 95% CI; and 5) studies that used overall survival (OS) and/or progression-free survival (PFS) as outcomes. For studies with overlapping data, only the most relevant articles with the largest datasets were included in the final analysis.

Data extraction
---------------

Two independent reviewers (X-PG and Y-HL) evaluated all potential articles for inclusion. Disagreements were resolved by discussion among all coauthors. The following information was collected: the first author's name, publication year, country (region) and ethnicity of the population, publication type, number of OC patients at baseline, age, year of recruitment, time of follow-up, treatment method, tumor stage, histological type, LMR cutoff value, method of obtaining cutoff value, OC diagnostic criteria, survival analysis methods, and prognostic end points (OS or PFS). HRs were extracted from multivariate or univariate analyses or Kaplan--Meier survival curves. If only Kaplan--Meier curves were provided, we extracted data from the survival curves using Engauge Digitizer v.4.1 software.[@b13-cmar-11-1907]

Quality assessment
------------------

Each study's methodological quality was assessed as per the Newcastle--Ottawa Scale (NOS),[@b14-cmar-11-1907] which was used to allocate a maximum of nine stars for selection quality of the study population, comparability, and outcome. The studies' quality scores ranged from 0 to 9, with 7--9 points indicating a high-quality study and 0--6 points indicating a low-quality study.

Statistical analyses
--------------------

The DerSimonian and Laird random-effects model of inverse variance methods was used to estimate the pooled HRs and 95% CIs. Unless otherwise stated, we used the most fully adjusted RRs from each study, and the low LMR group was treated as the reference group. If the studies used different reference groups to estimate the LMR HR for OS/PFS, we used an Excel macro file to transform the reference group.[@b15-cmar-11-1907]

The random-effects model was chosen a priori, because it is considered to be more conservative than the fixed-effects model and it accounts for both within- and between-study heterogeneity.[@b16-cmar-11-1907] Between-study heterogeneity was tested using Cochran's *Q* test and Higgins *I*^2^ statistic (higher *I*^2^ values denote greater heterogeneity).[@b17-cmar-11-1907] We performed subgroup analyses for both OS and PFS to examine the robustness of the results by age (\<55 vs ≥55 years), LMR cutoff value (≤3.0 vs \>3.0), sample size (≤200 vs \>200), and NOS score (\<7 and ≥7 points). Influence analysis was also conducted to assess the effect of a single study on the pooled estimates.[@b18-cmar-11-1907] These variables were also analyzed as covariates in the meta-regression analysis. Publication bias was assessed by visually inspecting funnel plots and quantitatively evaluated using Egger's and Begg's linear regression asymmetry tests.[@b17-cmar-11-1907] All data were analyzed using Stata software, version 11.0 (StataCorp LP, College Station, TX, USA), and a two-sided *P*\<0.05 was considered statistically significant.

Results
=======

Search results
--------------

The electronic database searches identified 1,018 articles ([Figure 1](#f1-cmar-11-1907){ref-type="fig"}), of which 180 duplications were excluded by Endnote. After assessing titles and abstracts and screening full texts, 824 unrelated articles were excluded. For the remaining 14 potentially eligible articles, 2 duplicate studies, 1 duplicate study,[@b19-cmar-11-1907] and 1 study with incomplete data[@b20-cmar-11-1907] were further excluded. Finally, 12 studies were included.[@b5-cmar-11-1907]--[@b11-cmar-11-1907],[@b21-cmar-11-1907]--[@b25-cmar-11-1907]

Characteristics of the included studies
---------------------------------------

[Table 1](#t1-cmar-11-1907){ref-type="table"} summarizes the characteristics of the included studies. In total, 3,346 OC patients (weighted age: 55.8 years) were included, with a follow-up period ranging from 23.6 to 58 months. All studies were published in 2016 or later. The number of patients per study ranged from 42 to 672. Eight studies were conducted among Chinese patients, three among Korean patients, and one among American Caucasian patients. The LMR cutoff values ranged from 1.85 to 4.35. The overall NOS scores ranged from 5 to 8 points ([Table S2](#SD2-cmar-11-1907){ref-type="supplementary-material"}). Most cases were EOC, and 76.5% were stage III/IV. Among these studies, three investigated only OS, while nine investigated both OS and PFS.

Association between LMR and OS among OC patients
------------------------------------------------

Twelve studies involving 3,346 patients reported LMR and OS data among OC cases.[@b5-cmar-11-1907]--[@b11-cmar-11-1907],[@b21-cmar-11-1907]--[@b25-cmar-11-1907] Increased LMR was associated with improved OS (pooled HR: 1.85, 95% CI: 1.50--2.28, *P*\<0.001) with significant between-study heterogeneity (*P*\<0.001, *I*^2^=76.5%; [Table 2](#t2-cmar-11-1907){ref-type="table"} and [Figure 2A](#f2-cmar-11-1907){ref-type="fig"}). The association persisted after reanalyzing studies among Asian patients or those with only EOC. Stratified analyses for age, LMR cutoff values, sample size, and NOS score revealed significant interactions for age (*P* for interaction =0.017) and LMR cutoff values (*P* for interaction =0.025). The protective effect of elevated LMR was more evident among younger patients than older patients (HR: 2.28 vs 1.47) and among studies using an LMR cutoff of \>3.0 than in those using ≤3.0 (HR: 2.09 vs 1.38). Meta-regression analysis further confirmed that age, but not LMR cutoff values, significantly contributed to inter-study heterogeneity (*P* for regression =0.004 and 0.153; [Table S3](#SD3-cmar-11-1907){ref-type="supplementary-material"}).

Association between LMR and PFS in OC patients
----------------------------------------------

Eight studies[@b5-cmar-11-1907]--[@b9-cmar-11-1907],[@b21-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907] involving 2,114 patients reported data for the association between LMR and PFS among OC patients, and all studies were conducted among Asian patients. Similar to OS, the random-effects combined analysis demonstrated that LMR was positively and significantly associated with PFS (pooled HR: 1.70, 95% CI: 1.49--1.94, *P*\<0.001) but with low between-study heterogeneity (*I*^2^=24.4%; *P*=0.234; [Table 2](#t2-cmar-11-1907){ref-type="table"} and [Figure 2B](#f2-cmar-11-1907){ref-type="fig"}). The result was similar among studies with only EOC cases. Stratified analyses suggested that the association did not differ among NOS scores, LMR cutoff values, and age strata (*P* interaction range =0.066--0.987). Meta-regression analysis also revealed that publication year, age, NOS score, sample size, and LMR cutoff value did not significantly contribute to heterogeneity (*P* for regression range =0.086--0.982).

Sensitivity analysis and bias
-----------------------------

The sensitivity analyses indicated that the pooled HRs were not obviously influenced by any single study for either OS or PFS ([Table 2](#t2-cmar-11-1907){ref-type="table"}).

Both Egger's and Begg's tests revealed no significant publication bias, and the *P*-values were 0.732 and 0.272 for OS and 1.000 and 0.887 for PFS. The funnel plots also showed no evidence of publication bias for either OS or PFS ([Figure 3](#f3-cmar-11-1907){ref-type="fig"}).

Discussion
==========

In this meta-analysis, we first report the prognostic value of pretreatment LMR among OC patients. Our results indicate that higher pretreatment LMR levels are associated with increased OS and PFS among OC patients. Substantial heterogeneity was observed for OS; further subgroup and meta-regression analyses indicated that age contributed to this heterogeneity, and these associations were more evident among younger patients than older populations.

In recent years, several prognostic indicators derived from peripheral blood, such as LMR, have been widely investigated as useful prognostic markers in cancers. LMR has been identified as an independent prognostic factor in patients with various cancers, such as head and neck,[@b26-cmar-11-1907] pancreatic,[@b27-cmar-11-1907] colorectal,[@b28-cmar-11-1907] hepatocellular,[@b29-cmar-11-1907] and breast cancers.[@b30-cmar-11-1907] Our results were consistent with findings from these studies, showing that higher LMR ratios may improve cancer prognoses.

The exact mechanisms by which LMR has some prognostic relevance in OC patients were still unknown. According to the current evidence, lymphopenia might weaken the efficacy of the immune system and be associated with worse prognosis in cancers; cell-mediated cytotoxicity may be attenuated if the level of effector T cells is insufficient.[@b31-cmar-11-1907] Circulating monocytes may contribute to both tumor growth and reduced immunosurveillance through differentiating into macrophages after infiltrating a tumor and then respond to the wide spectrum of chemokines and growth or differentiation factors.[@b31-cmar-11-1907] Thus, the prognostic effect of LMR among OC patients can be assumed to be related to tumor-infiltrating immune cells, such as tumor-infiltrating lymphocytes (TILs), or tumor-associated macrophages. Circulating TILs, as direct measures of intratumoral immunity, may contribute to cancer growth and spread.[@b32-cmar-11-1907] In OC tumor tissue sections, intraepithelial CD8+ TILs correlated with good outcome, and a high ratio of CD8+/FoxP3+ T regulatory cells was beneficial to survival.[@b33-cmar-11-1907] Recent epidemiological studies have also confirmed that the presence of TILs was associated with improved clinical outcomes in OC patients.[@b34-cmar-11-1907]--[@b36-cmar-11-1907] Peripheral blood-based parameters (eg, LMR) have been studied as a surrogate measures of intratumoral immunity that reflect a host's immune response.[@b4-cmar-11-1907] LMR has been shown a statistically significant correlation with CD8+ TILs among patients with breast cancer.[@b37-cmar-11-1907] Tumor-associated macrophages (TAMs) have been suggested to be involved in accelerating angiogenesis, invasion, migration, and metastasis and suppress the body's autoimmune response against tumor cells.[@b38-cmar-11-1907],[@b39-cmar-11-1907] In addition, LMR had been supposed to reflect the TIL/TAM ratio, as the circulating levels of lymphocytes and monocytes may indicate the formation or the presence of TILs and TAMs, and significant correlation was observed between the LMR and the TIL/TAM ratio.[@b31-cmar-11-1907] Immunotherapy has emerged as one of the most promising approaches for OC treatment,[@b40-cmar-11-1907] and change in the LMR has been supposed to be an early surrogate marker of the efficacy of nivolumab monotherapy.[@b41-cmar-11-1907] Thus, LMR represents the balance between the host's immune status and the degree of tumor progression, and it may therefore be a prognostic biomarker among OC patients.

Subgroup analyses indicated that the favorable prognostic effect of pretreatment LMR for OS was more evident in studies conducted among younger (\<55 years) than older patients (≥55 years; *P* for interaction =0.017), which was further confirmed by meta-regression analysis (*P*=0.004). One explanation for our finding is that human aging is characterized by a gradual increase in subclinical chronic inflammation, and older people are more likely to get chronic inflammatory diseases.[@b42-cmar-11-1907] The greater severity of the inflammatory state among older OC patients may weaken the LMR's protective prognostic effect. In addition, older patients responded more efficiently to immunotherapy, such as programmed death-ligand 1 (nivolumab and pembrolizumab), and PD-L1 (atezolizumab) inhibitors also confirmed this finding.[@b43-cmar-11-1907],[@b44-cmar-11-1907]

Some limitations of this meta-analysis should also be considered. First, between-study heterogeneity was significant for OS (*I*^2^: 76.5%). Based on subgroup and meta-regression analyses, age was the main source of heterogeneity, and the pooled HR results showed consistent positive relationships. Second, most studies included herein were performed among Asian patients, while only one study examined OS among Caucasian patients,[@b10-cmar-11-1907] and no relevant studies were found for African patients. Thus, the findings of the present study might be limited to Asian patients, and the prognostic effects of LMR for other populations (eg, Caucasian or African) still need further confirmation. Third, the studies included herein differed in how the covariates were adjusted. However, the pooled estimates were similar between the maximal and minimal numbers of covariate adjustment analyses for both OS and PFS, indicating that these confounders were unlikely to significantly bias our findings (data not shown). Fourth, categorical analysis did not allow detecting the best cutoff point, which invites further studies to solve this problem. Fifth, all included studies were retrospective single-center studies, and the bias was unavoidable.

Conclusion
==========

This meta-analysis demonstrated that higher pretreatment LMR values were associated with more favorable outcomes among OC patients, and the associations were stronger for younger patients than older patients. Future large-scale prospective clinical trials are needed to confirm the LMR's prognostic effect and its cutoff value among OC patients. Therefore, LMR is a readily available, routinely measured, and inexpensive inflammatory biomarker, and if causation and cutoff value of LMR was established, LMR could be easily applied in daily clinical practice.

Supplementary materials
=======================

Detailed search strategies for each database
--------------------------------------------

### PubMed (N=215)

1.  \#1: lymphocyte-to-monocyte OR lymphocyte monocyte OR lymphocyte-monocyte OR lymphocyte to monocyte OR lymphocyte/monocyte OR LMR

2.  \#2: ((cancer\* OR carcinoma\* OR neoplasm\* OR malignan\* OR tumour\* OR tumor\*) AND (ovary OR ovarian)) OR "Ovarian Neoplasms"\[mesh\]

3.  \#3: \#1 AND \#2

### Embase (N=385)

1.  \#1: ((cancer\* OR carcinoma\* OR neoplasm\* OR malignan\* OR tumour\* OR tumor\*) AND (ovary OR ovarian)) OR ('ovarian neoplasms'/exp)

2.  \#2: ('lymphocyte to monocyte') OR (lymphocyte AND monocyte) OR ('lymphocyte monocyte') OR (lymphocyte AND to AND monocyte) OR (LMR) OR (lymphocyte?monocyte)

3.  \#3: \#1 AND \#2

### Web of science (N=160)

1.  \#1 (Ovarian Neoplasms) OR ((cancer\* OR carcinoma\* OR neoplasm\* OR malignan\* OR tumour\* OR tumor\*) AND (ovary OR ovarian))

2.  \#2 (lymphocyte-to-monocyte ratio OR "lymphocyte monocyte ratio" OR "lymphocyte to monocyte ratio" OR LMR)

3.  \#3: \#1 AND \#2

### Wanfang (N=165)

1.  \#1 摘要:(卵巢癌+卵巢肿瘤)\*摘要:(淋巴细胞)\*摘 要:(单核细胞))

2.  \#2 摘要:(卵巢癌+卵巢肿瘤)\*摘要:(LMR) \#3 题名或关键词:(卵巢癌+卵巢肿瘤)\*题名或关键 词:(淋巴细胞)\*题名或关键词:(单核细胞)

3.  \#4 题名或关键词:(卵巢癌+卵巢肿瘤)\*题名或关键 词:(LMR)

4.  \#5 主题:(卵巢癌+卵巢肿瘤)\*主题:(淋巴细胞) \* 主题:(单核细胞)

5.  \#6 主题:(卵巢癌+卵巢肿瘤)\*主题:(LMR) \#7: \#1 OR \#2 OR \#3 OR \#4 OR \#5 OR \#6

### Chinese National Knowledge Infrastructure (CNKI; N=73)

1.  \#1 AB=('卵巢癌'+'卵巢肿瘤') and AB='淋巴 细胞' and AB='单核细胞'

2.  \#2 AB=('卵巢癌'+'卵巢肿瘤') and AB='LMR' \#3 TI=('卵巢癌'+'卵巢肿瘤') and TI='淋巴 细胞' and TI='单核细胞'

3.  \#4 TI=('卵巢癌'+'卵巢肿瘤') and TI='LMR' \#5 KY=('卵巢癌'+'卵巢肿瘤') and KY='淋巴 细胞' and KY='单核细胞'

4.  \#6 KY=('卵巢癌'+'卵巢肿瘤') and KY='LMR' \#7 SU=('卵巢癌'+'卵巢肿瘤') and SU='淋巴 细胞' and SU='单核细胞'

5.  \#8 SU=('卵巢癌'+'卵巢肿瘤') and SU='LMR' \#9: \#1 OR \#2 OR \#3 OR \#4 OR \#5 OR \#6 OR \#7 OR \#8

###### 

PRISMA 2009 checklist

  Section/topic                        No.   Checklist item                                                                                                                                                                                                                                                                                               Reported on page number
  ------------------------------------ ----- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------
  **Title**                                                                                                                                                                                                                                                                                                                                               
  Title                                1     Identify the report as a systematic review, meta-analysis, or both                                                                                                                                                                                                                                           1
  **Abstract**                                                                                                                                                                                                                                                                                                                                            
  Structured summary                   2     Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number   3
  **Introduction**                                                                                                                                                                                                                                                                                                                                        
  Rationale                            3     Describe the rationale for the review in the context of what is already known                                                                                                                                                                                                                                4, 5
  Objectives                           4     Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS)                                                                                                                                                    5
  **Methods**                                                                                                                                                                                                                                                                                                                                             
  Protocol and registration            5     Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if available, provide registration information including registration number                                                                                                                                   NA
  Eligibility criteria                 6     Specify study characteristics (eg, PICOS and length of follow-up) and report characteristics (eg, years considered, language, and publication status) used as criteria for eligibility, giving rationale                                                                                                     6
  Information sources                  7     Describe all information sources (eg, databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched                                                                                                                                      5
  Search                               8     Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated                                                                                                                                                                                 5, Supplementary materials, pages 1--2
  Study selection                      9     State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis)                                                                                                                                                       6
  Data collection process              10    Describe method of data extraction from reports (eg, piloted forms, independently, and in duplicate) and any processes for obtaining and confirming data from investigators                                                                                                                                  6
  Data items                           11    List and define all variables for which data were sought (eg, PICOS and funding sources) and any assumptions and simplifications made                                                                                                                                                                        6
  Risk of bias in individual studies   12    Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis                                                                                        7, [Table S2](#SD2-cmar-11-1907){ref-type="supplementary-material"}
  Summary measures                     13    State the principal summary measures (eg, risk ratio and difference in means)                                                                                                                                                                                                                                7
  Synthesis of results                 14    Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, *I*^2^) for each meta-analysis                                                                                                                                                       7
  Risk of bias across studies          15    Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias and selective reporting within studies)                                                                                                                                                                 7, 8
  Additional analyses                  16    Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta- regression), if done, indicating which were prespecified                                                                                                                                                                7
  **Results**                                                                                                                                                                                                                                                                                                                                             
  Study selection                      17    Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram                                                                                                                                               8, [Figure 1](#f1-cmar-11-1907){ref-type="fig"}
  Study characteristics                18    For each study, present characteristics for which data were extracted (eg, study size, PICOS, and follow-up period) and provide the citations                                                                                                                                                                8, [Table 1](#t1-cmar-11-1907){ref-type="table"}
  Risk of bias within studies          19    Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12)                                                                                                                                                                                                     10, [Table S3](#SD3-cmar-11-1907){ref-type="supplementary-material"}
  Results of individual studies        20    For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and CIs, ideally with a forest plot                                                                                                                       [Figure 2](#f2-cmar-11-1907){ref-type="fig"}
  Synthesis of results                 21    Present results of each meta-analysis done, including CIs and measures of consistency                                                                                                                                                                                                                        9, 10, [Table 2](#t2-cmar-11-1907){ref-type="table"}, [Figure 2](#f2-cmar-11-1907){ref-type="fig"}
  Risk of bias across studies          22    Present results of any assessment of risk of bias across studies (see item 15)                                                                                                                                                                                                                               10, [Table S3](#SD3-cmar-11-1907){ref-type="supplementary-material"}
  Additional analysis                  23    Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta- regression \[see item 16\])                                                                                                                                                                                        9, 10
  **Discussion**                                                                                                                                                                                                                                                                                                                                          
  Summary of evidence                  24    Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (eg, health care providers, users, and policy makers)                                                                                                                           10
  Limitations                          25    Discuss limitations at study and outcome level (eg, risk of bias), and at review level (eg, incomplete retrieval of identified research and reporting bias)                                                                                                                                                  12, 13
  Conclusions                          26    Provide a general interpretation of the results in the context of other evidence and implications for future research                                                                                                                                                                                        13
  **Funding**                                                                                                                                                                                                                                                                                                                                             
  Funding                              27    Describe sources of funding for the systematic review and other support (eg, supply of data); role of funders for the systematic review                                                                                                                                                                      13

**Note:** Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS Med*. 2009: 6(7): e1000100. <https://doi.org/10.1371/journal.pmed.1000100>. For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

**Abbreviation:** NA, not available.

###### 

Methodological quality of all studies based on NOS for assessing the quality of each included study

  Study                             Representa- tiveness of exposed cohort   Selection of non- exposed cohort   Assessment of exposure   Outcome not present at the start of the study   Compara- bility based on the design or analysis   Assessment of outcome   Follow- up long enough for outcomes   Adequacy of follow-up   Total score
  --------------------------------- ---------------------------------------- ---------------------------------- ------------------------ ----------------------------------------------- ------------------------------------------------- ----------------------- ------------------------------------- ----------------------- -------------
  Eo et al[@b45-cmar-11-1907]       1                                        1                                  1                        1                                               2                                                 0                       0                                     0                       6
  Sun and Song[@b46-cmar-11-1907]   1                                        1                                  1                        1                                               2                                                 0                       0                                     0                       6
  Wang et al[@b47-cmar-11-1907]     1                                        1                                  1                        1                                               2                                                 0                       0                                     0                       6
  Kwon et al[@b48-cmar-11-1907]     1                                        1                                  1                        1                                               2                                                 0                       0                                     0                       6
  Li et al[@b49-cmar-11-1907]       1                                        1                                  1                        1                                               2                                                 0                       1                                     1                       8
  Xiang et al[@b50-cmar-11-1907]    1                                        1                                  1                        1                                               1                                                 0                       0                                     1                       6
  Zhang et al[@b51-cmar-11-1907]    1                                        1                                  1                        1                                               1                                                 0                       0                                     0                       5
  Zhu et al[@b52-cmar-11-1907]      1                                        1                                  1                        1                                               2                                                 0                       1                                     0                       7
  Tang et al[@b53-cmar-11-1907]     1                                        1                                  1                        1                                               2                                                 0                       1                                     0                       7
  Tian[@b54-cmar-11-1907]           1                                        1                                  1                        1                                               1                                                 0                       1                                     1                       7
  Yang and Lo[@b55-cmar-11-1907]    1                                        1                                  1                        1                                               2                                                 0                       1                                     0                       7
  Kwon et al[@b56-cmar-11-1907]     1                                        1                                  1                        1                                               2                                                 0                       0                                     0                       6

**Abbreviation:** NOS, Newcastle--Ottawa Scale.

###### 

Meta-regression analyses of the associations between pretreatment LMR and survival among OC patients

                        Coefficient   Standard error   *T*-value   *P*-value   95% CI of intercept
  --------------------- ------------- ---------------- ----------- ----------- --------------------------
                                                                               
  **OS**                                                                       
  Year of publication   0.0820097     0.2491714        0.33        0.749       (--0.4731787, 0.6371981)
  Age                   −0.0738882    0.0200856        −3.68       0.004       (−0.1186417, −0.0291346)
  Sample size           −0.0008594    0.0005413        −1.59       0.143       (−0.0020655, 0.0003466)
  LMR cutoff value      0.2008357     0.129754         1.55        0.153       (−0.0882742, 0.4899455)
  NOS score             −0.1728062    0.1330581        −1.30       0.223       (−0.4692782, 0.1236658)
  **PFS**                                                                      
  Year of publication   −0.1952826    0.2098772        −0.93       0.388       (−0.7088336, 0.3182684)
  Age                   −0.0333006    0.0275148        −1.21       0.272       (−0.1006267, 0.0340256)
  Sample size           −0.0000113    0.0004759        −0.02       0.982       (−0.0011757, 0.0011531)
  LMR cutoff value      0.0189409     0.1054612        0.18        0.863       (−0.2391134, 0.2769952)
  NOS score             −0.1618594    0.0787455        −2.06       0.086       (−0.3545426, 0.0308238)

**Abbreviations:** LMR, lymphocyte-to-monocyte ratio; NOS, Newcastle--Ottawa Scale; OC, ovarian cancer; OS, overall survival; PFS, progression-free survival.
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![Forest plots of studies evaluating HRs of high pretreatment LMR among patients with OC for (**A**) OS and (**B**) PFS. Error bars indicate 95% CI.\
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![Funnel plots of studies evaluating HRs of high pretreatment LMR among patients with OC for (**A**) OS and (**B**) PFS.\
**Abbreviations:** LMR, lymphocyte-to-monocyte ratio; OC, ovarian cancer; OS, overall survival; PFS, progression-free survival.](cmar-11-1907Fig3){#f3-cmar-11-1907}

###### 

Characteristics of studies included in the meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                             Year   Country   Ethnicity   Duration of study conducted   Follow-up duration (months)   Age (years)[a](#tfn1-cmar-11-1907){ref-type="table-fn"}   Pathological type   Pathological subtypes, n (%)     No. of patients[b](#tfn2-cmar-11-1907){ref-type="table-fn"}   No. of stage I/II   No. of stage III/IV   Outcome      Cutoff value           Method of obtaining cutoff   NOS score
  --------------------------------- ------ --------- ----------- ----------------------------- ----------------------------- --------------------------------------------------------- ------------------- -------------------------------- ------------------------------------------------------------- ------------------- --------------------- ------------ ---------------------- ---------------------------- -----------
                                                                                                                                                                                                                                                                                                                                                                                                                     

  Eo et al[@b7-cmar-11-1907]        2016   Korea     Asian       2006.1-- 2013.12              NA                            54 (14--84)                                               EOC                 Serous: 132 (56.4)\              234                                                           97                  137                   OS and PFS   2.07                   ROC curve                    6
                                                                                                                                                                                                           Mucinous: 35 (15.0)\                                                                                                                                                                                      
                                                                                                                                                                                                           Clear cell: 35 (15.0)\                                                                                                                                                                                    
                                                                                                                                                                                                           Endometrioid: 21 (10.0)\                                                                                                                                                                                  
                                                                                                                                                                                                           Mixed epithelial: 5 (2.1)\                                                                                                                                                                                
                                                                                                                                                                                                           Others: 6 (2.6)                                                                                                                                                                                           

  Sun and Song[@b21-cmar-11-1907]   2016   China     Asian       2006.2-- 2014.4               NA                            55 (17--84)                                               EOC                 Serous: 103 (54.5)\              189                                                           78                  111                   OS and PFS   1.85                   ROC curve                    6
                                                                                                                                                                                                           Others: 86 (45.5)                                                                                                                                                                                         

  Wang et al[@b24-cmar-11-1907]     2016   China     Asian       2000.1-- 2013.12              NA                            56.1±10.2                                                 OC                  Serous: 214 (89.2)\              240                                                           59                  181                   OS           3.949                  ROC curve                    6
                                                                                                                                                                                                           Mucinous: 22 (9.2)\                                                                                                                                                                                       
                                                                                                                                                                                                           Endometrioid: 2 (0.8)\                                                                                                                                                                                    
                                                                                                                                                                                                           Clear cell: 2 (0.8)                                                                                                                                                                                       

  Kwon et al[@b9-cmar-11-1907]      2017   Korea     Asian       2009.4-- 2012.6\              NA                            70 (65--85)                                               EOC                 Serous: 33 (78.6)\               42                                                            0                   42                    OS and PFS   3.63                   ROC curve                    6
                                                                 2000--2010                                                                                                                                Non-serous: 9 (21.4)                                                                                                                                                                                      

  Li et al[@b10-cmar-11-1907]       2017   USA       Caucasian   2000--2010                    49.5 (0.1--175.3)             63 (28--93)                                               EOC                 High-grade serous: 525 (80.3)\   654                                                           121                 533                   OS and PFS   2.22                   ROC curve                    8
                                                                                                                                                                                                           Low-grade serous: 4 (0.6)\                                                                                                                                                                                
                                                                                                                                                                                                           Endometrioid: 71 (10.9)\                                                                                                                                                                                  
                                                                                                                                                                                                           Clear cell: 37 (5.7)\                                                                                                                                                                                     
                                                                                                                                                                                                           Mucinous: 17 (2.6)                                                                                                                                                                                        

  Xiang et al[@b11-cmar-11-1907]    2017   China     Asian       2011.1-- 2016.3\              23.6 (0.77--69.4)             53.3±13.6 (20--82)                                        OC                  Serous: 87 (65.4)\               124                                                           64                  69                    OS           4.35                   ROC curve                    6
                                                                 2007.1-- 2015.12                                                                                                                          Mucinous: 14 (10.5)\                                                                                                                                                                                      
                                                                                                                                                                                                           Endometrioid: 10 (7.5)\                                                                                                                                                                                   
                                                                                                                                                                                                           Clear cell: 5 (3.8)\                                                                                                                                                                                      
                                                                                                                                                                                                           Others: 17 (12.8)                                                                                                                                                                                         

  Zhang et al[@b5-cmar-11-1907]     2017   China     Asian       2007.1-- 2015.12              NA                            50 (24--76)                                               OC                  Serous: 123 (51.9)\              237                                                           67                  170                   OS and PFS   3.82                   NA                           5
                                                                                                                                                                                                           Non-serous: 114 (36.3)                                                                                                                                                                                    

  Zhu et al[@b6-cmar-11-1907]       2017   China     Asian       2008.6-- 2015.12              38 (5--103)                   55 (30--70)                                               EOC                 Serous: 484 (72.0)\              672                                                           0                   672                   OS and PFS   3.45                   ROC curve                    7
                                                                                                                                                                                                           Non-serous: 188 (28.0)                                                                                                                                                                                    

  Tang et al[@b22-cmar-11-1907]     2017   China     Asian       2005.1-- 2015.1               46 (2--120)                   52.2±12.0                                                 EOC                 Serous: 146 (68.2)\              214                                                           99                  115                   OS           3.85                   ROC curve                    7
                                                                                                                                                                                                           Non-serous: 68 (31.8)                                                                                                                                                                                     

  Tian[@b23-cmar-11-1907]           2017   China     Asian       2009.1-- 2011.7               58 (2--60)                    54 (14--76)                                               EOC                 Serous: 166 (62.2)\              267                                                           86                  181                   OS and PFS   3.09 (OS) 2.07 (PFS)   ROC curve                    7
                                                                                                                                                                                                           Mucinous: 21 (7.9)\                                                                                                                                                                                       
                                                                                                                                                                                                           Endometrioid: 65 (24.3)\                                                                                                                                                                                  
                                                                                                                                                                                                           Clear cell: 14 (5.2)\                                                                                                                                                                                     
                                                                                                                                                                                                           Others: 1 (0.4)                                                                                                                                                                                           

  Yang and Lo[@b25-cmar-11-1907]    2017   China     Asian       2005.1--2011.5                37 (1--112)                   54 (22--78)                                               EOC                 Serous: 206 (56.6)\              364                                                           52                  312                   OS and PFS   3.84                   ROC curve                    7
                                                                                                                                                                                                           Mucinous: 111 (30.5)\                                                                                                                                                                                     
                                                                                                                                                                                                           Endometrioid: 23 (6.3)\                                                                                                                                                                                   
                                                                                                                                                                                                           Others: 24 (6.6)                                                                                                                                                                                          

  Kwon et al[@b8-cmar-11-1907]      2018   Korea     Asian       2005.1--2011.5                NA                            50 (24--77)                                               OCCC                OCCC: 109 (100)                  109                                                           64                  45                    OS and PFS   4.2                    ROC curve                    6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Mean, median (range) of age at baseline.

Number of patients at baseline.

**Abbreviations:** EOC, epithelial ovarian cancer; NA, not available; NOS, Newcastle--Ottawa Scale; OC, ovarian cancer; OCCC, ovarian clear cell carcinoma; OS, overall survival; PFS, progression-free survival; ROC, receiver-operator characteristic.

###### 

Total, stratified, and sensitivity analyses of the associations between pretreatment LMR and survival among OC patients

  Groups                                                               OS                                                                                                                                           PFS                                                                                                                                                                                                         
  -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------- --------- ------ --------- ----------------------------------------------------------------------------------------------------------------------- ------------------- --------- ------ -------
                                                                                                                                                                                                                                                                                                                                                                                                                                
  **Overall**                                                          12[@b5-cmar-11-1907]--[@b11-cmar-11-1907],[@b21-cmar-11-1907]--[@b25-cmar-11-1907]                                                           1.85 (1.50--2.28)   \<0.001   76.5   \<0.001   8[@b5-cmar-11-1907]--[@b9-cmar-11-1907],[@b21-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]                     1.70 (1.49--1.94)   \<0.001   24.4   0.234
  **Asian only**                                                       11[@b5-cmar-11-1907]--[@b9-cmar-11-1907],[@b11-cmar-11-1907],[@b21-cmar-11-1907]--[@b25-cmar-11-1907]                                        1.97 (1.62--2.40)   \<0.001   67.0   0.001     8[@b5-cmar-11-1907]--[@b9-cmar-11-1907],[@b21-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]                     1.70 (1.49--1.94)   \<0.001   24.4   0.234
  **EOC only**                                                         8[@b6-cmar-11-1907],[@b7-cmar-11-1907],[@b9-cmar-11-1907],[@b10-cmar-11-1907],[@b21-cmar-11-1907]--[@b23-cmar-11-1907],[@b25-cmar-11-1907]   1.69 (1.34--2.13)   \<0.001   79.4   \<0.001   6[@b6-cmar-11-1907],[@b7-cmar-11-1907],[@b9-cmar-11-1907],[@b21-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]   1.64 (1.48--1.82)   \<0.001   0.0    0.483
  **Subgroup analyses**                                                                                                                                                                                                                                                                                                                                                                                                         
  Age (years)                                                                                                                                                                                                                                                                                                                                                                                                                   
   \<55                                                                7[@b5-cmar-11-1907],[@b7-cmar-11-1907],[@b8-cmar-11-1907],[@b11-cmar-11-1907],[@b22-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]    2.28 (1.72--3.01)   \<0.001   61.9   0.015     5[@b5-cmar-11-1907],[@b7-cmar-11-1907],[@b8-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]                       1.74 (1.37--2.20)   \<0.001   54.7   0.065
   ≥55                                                                 5[@b6-cmar-11-1907],[@b9-cmar-11-1907],[@b10-cmar-11-1907],[@b21-cmar-11-1907],[@b24-cmar-11-1907]                                           1.47 (1.17--1.85)   0.001     72.2   0.006     3[@b6-cmar-11-1907],[@b9-cmar-11-1907],[@b21-cmar-11-1907]                                                              1.70 (1.50--1.94)   \<0.001   0.0    0.811
  LMR cutoff values                                                                                                                                                                                                                                                                                                                                                                                                             
   ≤3.0                                                                3[@b7-cmar-11-1907],[@b10-cmar-11-1907],[@b21-cmar-11-1907]                                                                                  1.38 (1.06--1.80)   0.015     64.0   0.062     2[@b7-cmar-11-1907],[@b21-cmar-11-1907]                                                                                 1.81 (1.11--2.97)   0.018     65.3   0.090
   \>3.0                                                               9[@b5-cmar-11-1907],[@b6-cmar-11-1907],[@b8-cmar-11-1907],[@b9-cmar-11-1907],[@b11-cmar-11-1907],[@b22-cmar-11-1907]--[@b25-cmar-11-1907]    2.09 (1.63--2.67)   \<0.001   70.1   0.001     6[@b5-cmar-11-1907],[@b6-cmar-11-1907],[@b8-cmar-11-1907],[@b9-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]    1.72 (1.48--1.99)   \<0.001   18.0   0.297
  Sample size                                                                                                                                                                                                                                                                                                                                                                                                                   
   ≤200                                                                4[@b8-cmar-11-1907],[@b9-cmar-11-1907],[@b11-cmar-11-1907],[@b21-cmar-11-1907]                                                               1.59 (0.99--2.56)   0.057     37.8   0.186     3[@b8-cmar-11-1907],[@b9-cmar-11-1907],[@b21-cmar-11-1907]                                                              1.36 (0.83--2.20)   0.219     0.0    0.970
   \>200                                                               8[@b5-cmar-11-1907]--[@b7-cmar-11-1907],[@b10-cmar-11-1907],[@b22-cmar-11-1907]--[@b25-cmar-11-1907]                                         1.94 (1.50--2.50)   \<0.001   83.1   \<0.001   5[@b5-cmar-11-1907]--[@b7-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]                                         1.74 (1.48--2.06)   \<0.001   52.0   0.080
  NOS score                                                                                                                                                                                                                                                                                                                                                                                                                     
   \<7                                                                 7[@b5-cmar-11-1907],[@b7-cmar-11-1907]--[@b9-cmar-11-1907],[@b11-cmar-11-1907],[@b21-cmar-11-1907],[@b24-cmar-11-1907]                       1.94 (1.45--2.60)   \<0.001   57.1   0.030     5[@b5-cmar-11-1907],[@b7-cmar-11-1907]--[@b9-cmar-11-1907],[@b21-cmar-11-1907]                                          2.06 (1.65--2.59)   \<0.001   0.0    0.429
   ≥7                                                                  5[@b6-cmar-11-1907],[@b10-cmar-11-1907],[@b22-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]                                          1.79 (1.31--2.46)   \<0.001   86.7   \<0.001   3[@b6-cmar-11-1907],[@b23-cmar-11-1907],[@b25-cmar-11-1907]                                                             1.63 (1.46--1.81)   \<0.001   0.0    0.379
  **Influence analyses[e](#tfn8-cmar-11-1907){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                                                                            
   Minimal                                                             --                                                                                                                                           1.75 (1.43--2.13)   \<0.001   72.9   \<0.001   --                                                                                                                      1.64 (1.48--1.81)   \<0.001   0.0    0.560
   Maximal                                                             --                                                                                                                                           1.97 (1.62--2.40)   \<0.001   67.0   0.001     --                                                                                                                      1.76 (1.51--2.05)   \<0.001   23.0   0.254

**Notes:**

Number of studies.

RRs and 95% CIs were pooled by using the random-effects model (the DerSimonian and Laird method).

*P*-value of *Z*-test for the significance of pooled RRs and 95% CIs.

*P*-value of *Q*-test for between-study heterogeneity test.

Influence analysis was conducted by eliminating one study at a time; for OS, the excluded study was the study by Tang et al[@b22-cmar-11-1907] for minimal pooled RRs, and Li et al[@b10-cmar-11-1907] for the maximal pooled RRs; for PFS, the excluded study was the study by Zhang et al[@b5-cmar-11-1907] for minimal pooled RRs, and Tian[@b23-cmar-11-1907] for the maximal pooled RR.

**Abbreviations:** EOC, epithelial ovarian cancer; LMR, lymphocyte-to-monocyte ratio; NOS, Newcastle--Ottawa Scale; OC, ovarian cancer; OS, overall survival; PFS, progression-free survival.
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